The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer

被引:79
作者
Bull, SB
Ozcelik, H
Pinnaduwage, D
Blackstein, ME
Sutherland, DAJ
Pritchard, KI
Tzontcheva, AT
Sidlofsky, S
Hanna, WM
Qizilbash, AH
Tweeddale, ME
Fine, S
McCready, DR
Andrulis, IL
机构
[1] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Ctr Canc Genet, Toronto, ON M5G 1X5, Canada
[2] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada
[3] Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada
[4] Mt Sinai Hosp, Dept Surg, Toronto, ON M5G 1X5, Canada
[5] Toronto Sunnybrook & Womens Hlth Sci Ctr, Toronto, ON, Canada
[6] N York Gen Hosp, Toronto, ON, Canada
[7] Toronto Hosp, Toronto, ON M5T 2S8, Canada
[8] Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada
[9] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[10] Univ Toronto, Dept Anat & Med, Toronto, ON, Canada
[11] Univ Toronto, Dept Med Genet, Toronto, ON, Canada
[12] Univ Toronto, Dept Microbiol, Toronto, ON, Canada
[13] Credit Valley Hosp, Mississauga, ON, Canada
关键词
D O I
10.1200/JCO.2004.09.128
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Increases in neu/erbB-2 have been implicated in breast cancer prognosis, but do not predict all recurrences. On the basis of evidence that p53 mutation is involved in the development of human neoplasia, we examined the prognostic value of p53 alterations in combination with neu/erbB-2 amplification. Patients and Methods A consecutive series of women were observed for recurrence and death (median follow-up of 85 months) and tumors from 543 individuals were analyzed for p53 mutation status and neu/erbB-2 amplification. Exons 4 through 10 of the p53 gene were analyzed by single-stranded conformational polymorphism and mutations were confirmed by DNA sequencing. The association of p53 mutation status and neu/erbB-2 amplification with risk of recurrence and death was examined in survival analyses with traditional and histologic markers as prognostic factors. Results p53 mutations occurred in 24.5% of the axillary node-negative breast carcinomas. Mutations were more frequent in carcinomas with neu/erbB-2 amplification: 38.9% compared with only 20.9% in those without neu/erbB-2 amplification. We found elevated risks of disease recurrence and overall mortality in patients with both p53 mutation and neu/erbB-2 amplification in their tumor compared with patients with neither or only one of the alterations. This increase persisted with adjustment for other prognostic factors (relative risk, 2.32; P =.002 for recurrence; relative risk, 2.22; P =.004 for death). Conclusion Evaluation of tumors for p53 mutations may be beneficial to identify women at higher risk of disease recurrence and death when the tumor has neu/erbB-2 amplification, but in the absence of neu/erbB-2 amplification, the presence of p53 mutation may not provide additional independent prognostic information.
引用
收藏
页码:86 / 96
页数:11
相关论文
共 22 条
[1]  
Allred DC, 1998, MODERN PATHOL, V11, P155
[2]   neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer [J].
Andrulis, IL ;
Bull, SB ;
Blackstein, ME ;
Sutherland, D ;
Mak, C ;
Sidlofsky, S ;
Pritzker, KPH ;
Hartwick, RW ;
Hanna, W ;
Lickley, L ;
Wilkinson, R ;
Qizilbash, A ;
Ambus, U ;
Lipa, M ;
Weizel, H ;
Katz, A ;
Baida, M ;
Mariz, S ;
Stoik, G ;
Dacamara, P ;
Strongitharm, D ;
Geddie, W ;
McCready, D .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1340-1349
[3]  
[Anonymous], 1992, Lancet, V339, P1
[4]  
COX DR, 1972, J R STAT SOC B, V34, P187
[5]   Prognostic and predictive value of p53 and p21 in breast cancer [J].
Elledge, RM ;
Allred, DC .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 52 (1-3) :79-98
[6]   A RANDOMIZED CLINICAL-TRIAL EVALUATING SEQUENTIAL METHOTREXATE AND FLUOROURACIL IN THE TREATMENT OF PATIENTS WITH NODE-NEGATIVE BREAST-CANCER WHO HAVE ESTROGEN-RECEPTOR-NEGATIVE TUMORS [J].
FISHER, B ;
REDMOND, C ;
DIMITROV, NV ;
BOWMAN, D ;
LEGAULTPOISSON, S ;
WICKERHAM, DL ;
WOLMARK, N ;
FISHER, ER ;
MARGOLESE, R ;
SUTHERLAND, C ;
GLASS, A ;
FOSTER, R ;
CAPLAN, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (08) :473-478
[7]   A RANDOMIZED CLINICAL-TRIAL EVALUATING TAMOXIFEN IN THE TREATMENT OF PATIENTS WITH NODE-NEGATIVE BREAST-CANCER WHO HAVE ESTROGEN-RECEPTOR POSITIVE TUMORS [J].
FISHER, B ;
COSTANTINO, J ;
REDMOND, C ;
POISSON, R ;
BOWMAN, D ;
COUTURE, J ;
DIMITROV, NV ;
WOLMARK, N ;
WICKERHAM, DL ;
FISHER, ER ;
MARGOLESE, R ;
ROBIDOUX, A ;
SHIBATA, H ;
TERZ, J ;
PATERSON, AHG ;
FELDMAN, MI ;
FARRAR, W ;
EVANS, J ;
LICKLEY, HL ;
KETNER, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (08) :479-484
[8]  
Fitzgibbons PL, 2000, ARCH PATHOL LAB MED, V124, P966
[9]  
Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204
[10]  
GOLDHIRSCH A, 1989, NEW ENGL J MED, V320, P491